KMO and neurodegenerative disease: Further supporting the association of KMO in neurodegenerative diseases is the fact that the KMO inhibitor drug, JM6, has been noted for its ability to inhibit the loss of synapses, lower microglial activation, and increase life span in an HD mouse model [87].